About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
IP: Marta Vila Pueyo Collaborators: Laila Asskour, Victor José Gallardo Lopez, Erika Ivanna Araya Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 175000 Reference: PID2022-137287NA-I00 Duration: 01/09/2023 - 31/08/2026
IP: Marta Vila Pueyo Collaborators: - Funding agency: Fundació "La Caixa" Funding: 305100 Reference: LCF/BQ/PI23/11970015 Duration: 31/12/2023 - 30/12/2026
IP: Patricia Pozo Rosich Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna Funding agency: Instituto de Salud Carlos III Funding: 369930 Reference: PMP22/00189 Duration: 01/01/2023 - 31/12/2025
IP: Patricia Pozo Rosich Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Erika Ivanna Araya, Edoardo Caronna Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00406 Duration: 01/01/2022 - 30/06/2025
The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
